2023年第2版《NCCN肿瘤临床实践指南:肺癌筛查》更新解读

Interpretation of the NCCN clinical practice guidelines in oncology for lung cancer screening(version 2.2023)

肺癌是我国男性发病率第一、男性女性死亡率第一的恶性肿瘤,且发病率和死亡率仍在上升,肺癌筛查是早期发现肺癌与改善预后的重要举措。美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)每年更新《NCCN肺癌筛查临床实践指南》,2023年第2版于2023年5月发布。该指南依据最新研究进展以及高级别循证医学证据,制定肺癌尤其是肺癌中最常见和最受关注的非小细胞肺癌筛查标准,受到全球医生的广泛关注。本文将基于我国国情和中国肺癌筛查指南,对最新版《NCCN肺癌筛查临床实践指南》进行解读,以期为我国肺癌筛查工作提供最新参考。

Lung cancer is the malignant tumor with the highest incidence rate in men and the highest mortality rate in men and women in China,and the incidence and mortality rates are still increasing.Lung cancer screening is an important initiative for early detection of lung cancer and improvement of prognosis.The National Comprehensive Cancer Network(NCCN)updates the NCCN Clinical Practice Guidelines for Lung Cancer Screening annually,and the2023 V2 edition was released in May 2023.The guidelines are based on the latest research advances and high-level evidence-based medical evidence to establish screening criteria for lung cancer,especially for non-small cell lung cancer,which is the most common and highly regarded type of lung cancer,and has received widespread attention from physicians worldwide.In this article,the latest version of the guideline will be interpreted based on China's national situation and Chinese lung cancer screening guidelines,with the aim of providing an updated reference for lung cancer screening in China.